S&P 500 Futures
(0.38%) 5 125.75 points
Dow Jones Futures
(0.15%) 38 786 points
Nasdaq Futures
(0.72%) 17 734 points
Oil
(0.20%) $83.53
Gas
(-0.44%) $1.804
Gold
(-0.10%) $2 339.80
Silver
(0.12%) $27.40
Platinum
(0.27%) $925.30
USD/EUR
(0.03%) $0.934
USD/NOK
(-0.05%) $10.90
USD/GBP
(0.00%) $0.803
USD/RUB
(-0.17%) $93.03

Realtime updates for Dynavax Technologies [DVAXW]

Exchange: OTC Sector: Healthcare Industry: Drug Manufacturersā€”Specialty & Generic

Live Chart Being Loaded With Signals

Commentary ():

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe...

Stats
Today's Volume 0
Average Volume 0
Market Cap 0
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 0
ATR14 $0 (0.00%)

Dynavax Technologies Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dynavax Technologies Financials

Annual 2020
Revenue: $46.55M
Gross Profit: $32.64M (70.12 %)
EPS: $-0.750
Q3 2021
Revenue: $108.27M
Gross Profit: $48.18M (44.50 %)
EPS: $-0.240
Q2 2021
Revenue: $52.77M
Gross Profit: $37.92M (71.87 %)
EPS: $0
Q4 2020
Revenue: $46.55M
Gross Profit: $32.64M (70.12 %)
EPS: $-0.750

Financial Reports:

No articles found.

Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators